Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones

Molecular Endocrinology

Volumn 10, Issue 2, 1996, Pages 119-131

  Katzenellenbogen, John A ^a   O'Malley, Bert W ^b   Katzenellenbogen, Benita S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; STEROID RECEPTOR;

ANIMAL CELL; CELL INTERACTION; COMPLEX FORMATION; DNA BINDING; EFFECTOR CELL; GENE ACTIVATION; HORMONE ACTION; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; RECEPTOR BINDING; SHORT SURVEY;

ANIMALS; HUMANS; LIGANDS; RECEPTORS, STEROID;

ANIMALIA;

EID: 0030071445     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.10.2.119     Document Type: Short Survey

References (131)

1. Russell DW, Wilson JD 1994 Steroid 5 α-reductase: two genes/two enzymes. Annu Rev Biochem 63:25-61
2. Funder JW 1993 Mineralocorticoids, glucocorticoids, receptors and response elements. Science 259:1132-1133
3. Orti E, Bodwell JE, Munck A 1992 Phosphorylation of steroid hormone receptors. Endocr Rev 13:105-128
4. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor: identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458-4466
5. Katzenellenbogen BS, Montano M, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N 1995 Antiestrogens: mechanisms and actions in target cells. J Steroid Biochem Mol Biol 53:387-393
6. Pfahl M 1994 Vertebrate receptors: molecular biology, dimerization and response elements. Semin Cell Biol 5:95-105
7. Chambon P 1994 The retinoid signalling pathway: molecular and genetic analyses. Semin Cell Biol 5:115-125
8. Tora L, Gronemeyer H, Turcotte B, Gaub M-, Chambon P 1988 The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 333:185-188
9. Tung LT, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265
10. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP 1993 Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244-1255
11. McDonnell DP 1995 Unraveling the human progesterone receptor signal transduction pathway. Trends Endocrinol Metab 6:133-138
12. Wilson CM, McPhaul MJ 1994 A and B forms of the androgen receptor are present in human genital skin fibroblasts. Proc Natl Acad Sci USA 91:1234-1238
13. Oakley RH, Madhabananda S, Cidlowski JA, The isoform of the human glucocorticoid receptor: expression, biochemical properties and putative function. Program of the 77th Annual meeting of The Endocrine Society, Washington D.C., 1995 (Abstract 81)
14. McGuire WL, Chamness GC, Fuqua SAW 1991 Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571-1577
15. Fuqua SAW, Wolf DM 1995 Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 35:233-241
16. Miksicek RJ, Lei Y, Wang Y 1993 Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res Treat 26: 163-174
17. Friend KE, Ang LW, Shupnik MA 1995 Estrogen regulates the expression of several novel estrogen receptor mRNA isoforms in rat pituitary. Proc Natl Acad Sci USA 92:4367-4371
18. Skipper JK, Young LJ, Bergeron JM, Tetzlaff MT, Osborn CT, Crews D 1993 Identification of an isoform of the estrogen receptor messenger RNA lacking exon four and present in the brain. Proc Natl Acad Sci USA 90:7172-7175
19. Toney TW, Katzenellenbogen BS 1986 Antiestrogen action in the medial basal hypothalamus and pituitary of immature female rats: insights concerning relationships among estrogen, dopamine and prolactin. Endocrinology 119:2661-2669
20. Hayes JR, Rorke EA, Robertson DW, Katzenellenbogen BS, Katzenellenbogen JA 1981 Biological potency and uterine estrogen receptor interactions of the metabolites of the antiestrogens Cl628 and U23,469. Endocrinology 108:164-172
21. Robertson DW, Katzenellenbogen JA, Hayes JR, Katzenellenbogen BS 1982 Antiestrogen basicity-activity relationships: a comparison of the estrogen binding and antiuterotrophic potencies of several analogs of tamoxifen having altered basicity. J Med Chem 25:167-171
22. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS 1982 Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16:1-13
23. Kneifel MA, Leytus SP, Fletcher E, Weber T, Mangel WF, Katzenellenbogen BS 1982 Uterine plasminogen activator activity: modulation by steroid hormones. Endocrinology 111:493-499
24. Kneifel MA, Katzenellenbogen BS 1981 Comparative effects of estrogen and antiestrogen on plasma renin substrate levels and hepatic estrogen receptors in the rat. Endocrinology 108:545-552
25. Evans G, Bryant HU, Sato M, Turner RT 1993 Raloxifene is a tissue specific estrogen agonist. J Bone Miner Res 8 [Suppl 1]:S134
26. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY1394881 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
27. Sato M, Glasebrook AL, Bryant HU 1994 Raloxifene: a selective estrogen receptor modulator. J Bone Miner Met 12 [Suppl 2]:S9-S20
28. Draper MW, Flowers DE, Hustler WJ, Nield JA 1993 Effects of raloxifene (LY139481 HCl) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In: Christiansen C, Riis B (eds) Proceedings of the 4th International Symposium on Osteoporosis and Consensus Development Conference. Handelstrykkerict Aalborg APS, Aalborg, Denmark, pp 119-121
29. Termine JD 1994 Therapy for postmenopausal osteoporosis based on fundamental disease etiology and pathophysiology. J Bone Miner Met 12 [Suppl 2]:S25-S28
30. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU 1995 Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci 761:355-360
31. Love RR, Mazess RB, Barden HS, Epstein SE, Newcomb PA, Jordan VC, Carbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
32. Love RR, Newcomb PA, Wiebe DA, Surazicz TS, Jordan VC, Carone PP, DeMets DL 1990 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. J Natl Cancer Inst 82:1327-1332
33. Wolf DM, Jordan VC 1992 Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 45:118-128
34. Jordan VC 1995 Tamoxifen and tumorigenicity: a predictable concern. J Natl Cancer Inst 87:623-626
35. Jordan VC, Assikis VJ 1995 Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1:467-472
36. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1-15
37. Wakeling AE, Bowler J 1988 Biology and mode of action of pure antiestrogens. J Steroid Biochem 30:141-147
38. Wakeling AE, Dukes M, Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
39. Weaver CA, Springer PA, Katzenellenbogen BS 1988 Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. Mol Endocrinol 2:936-945
40. Mymryk JS, Archer TK 1995 Dissection of progesterone receptor-mediated chromatin remodeling and transcriptional activation in vivo. Genes Dev 9:1366-1376
41. Montano MM, Müller V, Trobaugh A, Katzenellenbogen BS 1995 The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814-825
42. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30
43. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
44. McDonnell DP, Goldman ME 1994 RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem 269: 11945-11949
45. Kraus WL, Weis KE, Katzenellenbogen BS 1995 Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 15:1847-1857
46. Berry M, Metzger D, Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818
47. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel SF 1984 Bioactivities, estrogen receptor interactions and plasminogen activator inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119
48. Wei LL, Mangel WF, Katzenellenbogen BS 1985 Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor in vivo and in vitro. J Steroid Biochem 23:875-881
49. Eckert RL, Katzenellenbogen BS 1982 Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 42:139-144
50. Fujimoto N, Katzenellenbogen BS 1994 Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen-selectivity and promoter-dependence. Mol Endocrinol 8:296-304
51. 1 pituitary tumor cells are gene specific. Mol Endocrinol 6:529-535
52. Ramkumar T, Adler S 1995 Differential positive and negative transcriptional regulation by tamoxifen. Endocrinology 136:536-542
53. Yang NN, Hardikar S, Kim J 1993 Raloxifene, an antiestrogen, simulates the effects of estrogen on inhibiting bone resorption through regulating TGF β-3 expression in bone. J Bone Miner Res 8[Suppl 1]:S118
54. Yang NN, Hardikar S, Venugopalan M, Estrogen receptor regulates the transforming growth factor β3 (TGF-β3) gene expression through a novel mechanism. Program of the 77th Annual Meeting of The Endocrine Society, Washington, D.C., 1995, (Abstract 235)
55. Ehrlich P 1897 Die Wertbemessung des diphtherieheilserums und deren theoretische grundlagen. Klin Jahr 6:299-326
56. Langley JN 1905 On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol (Lond) 33:374-413
57. Clark AJ 1926 The reaction between acetyl choline and muscle cells. J Physiol (Lond) 61:530-546
58. Gaddum JH 1926 The action of adrenalin and ergotamine on the uterus of the rabbit. J Physiol (Lond) 61: 141-150
59. Ariëns EJ, Simonis AM 1964 A molecular basis for drug action. J Pharm Pharmacol 16:137-157
60. Stephenson RP 1956 A modification of receptor theory. Br J Pharmacol Chemother 11:379-393
61. Jensen EV, Jacobson HI 1962 Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18:387-414
62. Mueller GC, Herranen AM, Jervell KF 1958 Studies on the mechanism of action of estrogens. Recent Prog Horm Res 14:95-129
63. Mueller GC, Gorski J, Aizawa Y 1961 The role of protein synthesis in early estrogen action. Proc Natl Acad Sci USA 47:164-169
64. O'Malley BW, McGuire WL, Kohler PO, Koreman SG 1969 Studies on the mechanism of steroid hormone regulation of synthesis of specific proteins. Recent Prog Horm Res 25:105-160
65. O'Malley BW, Means AR 1974 Female steroid hormones and target cell nuclei. Science 183:610-620
66. Yamamoto KR, Alberts BM 1976 Steroid receptors: elements for modulation of eukaryotic transcription. Annu Rev Biochem 45:721-746
67. Katzenellenbogen BS, Gorski J 1975 Estrogen actions on syntheses of macromolecules in target cells. In: Litwack G (ed) Biochemical Action of Hormones. Academic Press, New York, vol 3:187-243
68. Gorski J, Gannon F 1976 Current models of steroid hormone action: a critique. Annu Rev Physiol 38:425-450
69. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889-895
70. Gronemeyer H 1991 Transcription activation by estrogen and progesterone receptors. Annu Rev Genet 25: 89-123
71. Katzenellenbogen JA 1992 Probes for steroid receptors - studies at the molecular, cellular, and whole organism levels. In: Proceedings of The Robert A. Welch Foundation Conference on Chemical Research: XXXV. Chemistry at the Frontiers of Medicine. Robert A. Welch Foundation, Houston, TX, pp 229-257
72. Truss M, Beato M 1993 Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 14:459-479
73. Tsai M-J, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
74. 73a. Simons Jr SS, Oshima H, Szapary D 1992 Higher levels of control: moduation of steroid hormone-regulated gene transcription. Mol Endocrinol 6:995-1002
75. Ariëns EJ, Rodrigues De Miranda JF 1979 The receptor concept: recent experimental and theoretical developments. In: Gualtiere F, Giannella M, Melchoirre C (eds) Recent Advances in Receptor Chemistry. Elsevier/North-Holland Biomedical Press, Amsterdam, pp 1-37
76. Bourne HR, Roberts JM 1987 Drug receptors and pharmacodynamics. In: Katzung BG (ed) Basic and Clinical Pharmacology. Appleton & Lange, Norwalk, CT, pp 9-22
77. Nogrady T 1988 Receptor-effector theories. In: Nogrady T (ed) Medicinal Chemistry: A Biochemical Approach, ed. 2. Oxford University Press, New York, pp 58-91
78. Ross EM 1990 Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) The Pharmacological Basis of Therapeutics, ed. 8. Pergamon Press, New York, pp 33-48
79. Hulme EC (ed) 1990 Receptor-Effector Coupling: A Practical Approach. Oxford University Press, New York
80. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL 1991 Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815
81. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR 1990 Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249:1266-1272
82. Ing NH, Beekman JM, Tsai SY, Tsai M-J, O'Malley BW 1992 Members of the steroid hormone receptor superfamily interact with TFIIB (S300II). J Biol Chem 267: 17617-17623
83. Baniahmad A, Ha I, Reinberg D, Tsai SY, Tsai M-J, O'Malley BW 1993 Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci USA 90:8832-8836
84. Blanco J, Wang I-M, Tsai SY, Tsai M-J, O'Malley BW, Jurutka PW, Haussler MR, Ozato K 1995 TFIIB and vitamin D receptor cooperatively activate ligand dependent transcription. Proc Natl Acad Sci USA 92:1535-1539
85. Zawel L, Reinberg D 1995 Common themes in assembly and function of eukaryotic transcription complexes. Annu Rev Biochem 64:533-561
86. Ptashne M, Gann AAF 1990 Activators and targets. Nature 346:329-331
87. Flanagan PM, Kelleher RJ, Sayre MH, Tschochner H, Kornberg RD 1991 A mediator required for activation of RNA polymerase II transcription in vitro. Nature 350: 436-438
88. Meyer ME, Gronemeyer H, Turcotte B, Bocquel M, Tasset D, Chambon P 1989 Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57:433-442
89. Conneely OM, Kettelberger DM, Tsai M-J, O'Malley BW 1989 Promoter specific activating domains of the chicken progesterone receptor. In: Roy AK, Clark J (eds) Gene Regulation by Steroid Hormones IV. Springer-Verlag, New York, pp 220-223
90. McDonnell DP, Vegeto E, O'Malley BW 1992 Identification of a negative regulatory function for steroid receptors. Proc Natl Acad Sci USA 89:10563-10567
91. Onate SA, Tsai SY, Tsai M-J, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357
92. Allan GF, Leng XH, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW 1992 Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267: 19513-19520
93. Beekman JM, Allan GF, Tsai SY, Tsai M-J, O'Malley BW 1993 Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7:1266-1274
94. Baniahmad A, Leng X, Burris TP, Tsai SY, Tsai M-J, O'Malley BW 1995 The τ4 activation domain of the thyroid hormone receptor is required to release a corepressor(s) necessary for transcriptional silencing. Mol Cell Biol 15:76-86
95. Nawaz Z, Tsai M-J, O'Malley BW 1995 Specific mutations in the ligand binding domain selectively abolish the silencing function of human thyroid receptor β. Proc Natl Acad Sci USA 92:11691-11695
96. Damm K, Evans RM 1993 Identification of a domain required for oncogenic activity and transcriptional suppression by v-erbA and thyroid-hormone receptor alpha. Proc Natl Acad Sci USA 90:10668-10672
97. Baniahmad A, Steiner C, Kohne AC, Renkawitz R 1990 Modular structure of a chicken lysozyme silencer: involvement of an unusual thyroid hormone receptor binding site. Cell 61:505-514
98. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457
99. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Glass B, Kurokawa R, Ryan A, Kamel Y, Söderström M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404
100. Baniahmad C, Nawaz Z, Baniahmad A, Gleeson MAG, Tsai M-J, O'Malley BW 1995 Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. Mol Endocrinol 9:34-43
101. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M 1994 Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455-1458
102. Cavaillés V, Dauvois S, Danielian PS, Parker MG 1994 Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91:10009-10013
103. Cavaillés V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, Parker MG 1995 Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 14:3741-3751
104. Landel CC, Kushner PJ, Greene GL 1994 The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol 8:1407-1419
105. Le Douarin B, Zechel C, Garnier J, Luyz Y, Tora L, Pierrat B, Heery D, Gronemeyer H, Chambon P, Losson R 1995 The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 14:2020-2033
106. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD 1995 Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374:91-94
107. Tsai SY, Carlstedt-Duke J, Weigel NL, Dahlman K, Gustafsson J-A, Tsai M-J, O'Malley BW 1988 Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell 55:361-369
108. Baniahmad C, Muller M, Altschmied J, Renkawitz R 1991 Co-operative binding of the glucocorticoid receptor DNA binding domain is one of at least two mechanisms for synergism. J Mol Biol 222:155-165
109. Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443-456
110. Dubik D, Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7:1587-1594
111. Wu-Peng XS, Pugliese TE, Dickerman HW, Pentecost BT 1992 Delineation of sites mediating estrogen regulation of the rat creatine kinase B gene. Mol Endocrinol 6:231-240
112. Krishnan V, Wang X, Safe S 1994 Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 269:15912-15917
113. Hyder SM, Nawaz Z, Chiapetta C, Yokoyama K, Stancel GM 1995 The protooncogene c-jun contains an unusual estrogen-inducible enhancer within the coding sequence. J Biol Chem 270:8506-8513
114. Yoshinaga SK, Peterson CL, Herskowitz I, Yamamoto KR 1992 Roles of SW1, SW2 and SW3 proteins for transcriptional enhancement by steroid receptors. Science 258:1598-1604
115. Burns K, Duggan B, Atkinson EA, Famulski KS, Nemer M, Bleackley RC, Michalak M 1994 Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature 367:476-480
116. Burris TP, Nawaz Z, Tsai M-J, O'Malley BW 1995 A nuclear hormone receptor-associated protein that inhibits transactivation by the thyroid hormone and retinoic acid receptors. Proc Natl Acad Sci USA 92:9525-9529
117. Hager GL, Archer TK 1991 The interaction of steroid receptors with chromatin. In: Parker MG (ed) Nuclear Hormone Receptors. Academic Press, London, pp 217-234
118. Miner JN, Yamamoto KR 1991 Regulatory crosstalk at composite response elements. Trends Biochem Sci 16: 423-426
119. Pakdel F, Katzenellenbogen BS 1992 Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 267:3429-3437
120. Wrenn CK, Katzenellenbogen BS 1993 Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem 268:24089-24098
121. Katzenellenbogen BS, Bhardwaj B, Fang H, Ince BA, Pakdel F, Reese JC, Schodin DJ, Wrenn CK 1993 Hormone binding and transcription activation by estrogen receptors: analyses using mammalian and yeast systems. J Steroid Biochem Mol Biol 47:39-48
122. Danielian PS, White R, Hoare SA, Fawell SF, Parker MG 1993 Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7:232-240
123. Jiang S-Y, Langan-Fahey SM, Stella AL, McCague R, Jordan VC 1992 Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the phar-macology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNA's for ER. Mol Endocrinol 6:2167-2174
124. Lefstin JA, Thomas JR, Yamamoto KR 1994 Influence of a steroid receptor DNA-binding domain on transcriptional regulatory functions. Genes Dev 8:2842-2856
125. 123a. Oshima H, Simons Jr SS 1992 Modulation of transcription factor activity by a distant steroid modulatory element. Mol Endocrinol 6:416-428
126. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the nuclear receptor RXR-α. Nature 375:377-382
127. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-689
128. Wagner RL, Apriletti JW, NcGrath ME, West BL, Baxter JD, Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378:690-697
129. Burgen ASV 1970 Receptor mechanisms. Annu Rev Pharmacol 10:7-15
130. Koshland DE, Neet KE 1968 The catalytic and regulatory properties of enzymes. Annu Rev Biochem 37:359-410
131. Belleau B 1964 A molecular theory of drug action based on induced conformational perturbation of receptors. J Med Chem 7:776-785